Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

A 15-year-old boy was correctly diagnosed with a rare skin condition after initially being misdiagnosed.

Researchers found a new area on chromosome 2 linked to a genetic hair loss condition.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

A new tool can predict hair regrowth in patchy alopecia areata patients.

Early hair loss may indicate prostate issues.

Early hair loss may indicate future prostate issues.

A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.

Flutamide may slightly improve hair loss in women, but finasteride does not work.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Low vitamin D might be one of several factors involved in the hair loss condition alopecia areata.

The 2940-nm Er: YAG laser combined with medication is a safe and better treatment for male hair loss than medication alone.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib may help treat severe hair loss, but more research is needed.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

The evaluation system improved patient selection for hair loss surgery, leading to better results and satisfaction.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Hair loss significantly lowers life quality, especially in young men, with most patients unhappy with treatment effectiveness.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.